Jun Hwa Hong

Dr. Jun Hwa Hong

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2022 in Trends in Endocrinology & Metabolism
Verified
Journal Article
Closed access
JMJun Moon
Jun Moon
JHJun Hwa Hong
Jun Hwa Hong
YJYong Jin Jung
Yong Jin Jung
EFEle Ferrannini
Ele Ferrannini
MNMichael A. Nauck
Michael A. Nauck
SLSoo Lim
Soo Lim

31 October 2020 in Diabetes & Metabolism Journal
Verified
Journal Article
Open access
PDF file
MHMyung-haeng Hur
Myung-haeng Hur
MLMi-Kyoung Lee
Mi-Kyoung Lee
KSKayeon Seong
Kayeon Seong
JHJun Hwa Hong
Jun Hwa Hong
Hur MH, et al. Diabetes Metab J. 2020 Jan;44:e16. https://doi.org/10.4093/dmj.2019.0125

YLYu-Jin Lee
Yu-Jin Lee
JHJun Hwa Hong
Jun Hwa Hong
MHMyung-haeng Hur
Myung-haeng Hur
ESEun-Young Seo
Eun-Young Seo
Background: This study is a preliminary study to examine the effect of a virtual reality exercise program (VREP) on type 2 diabetes patients. Method: This is a randomized controlled trial for patients with type 2 diabetes (glycated hemoglobin ≥ 6.5%), diagnosed by a specialist. The virtual reality environment was set up by attaching an IoT sensor to an indoor bicycle and linking it with a smartphone, enabling exercise in an immersive virtual reality through a head-mounted display. The VREP was implemented three times a week, for two weeks. The blood glucose, body composition, and exercise immersion were analyzed at baseline, and two weeks before and after the experimental intervention. Result: After VREP application, the mean blood glucose (F = 12.001 p < 0.001) and serum fructosamine (F = 3.274, p = 0.016) were significantly lower in the virtual reality therapy (VRT) and indoor bicycle exercise (IBE) groups than in the control group. There was no significant difference in the body mass index between the three groups; however, the muscle mass of participants in the VRT and IBE groups significantly increased compared with that of the control (F = 4.445, p = 0.003). Additionally, exercise immersion was significantly increased in the VRT group compared with that in the IBE and control groups. Conclusion: A two week VREP had a positive effect on blood glucose, muscle mass, and exercise immersion in patients with type 2 diabetes, and is highly recommended as an effective intervention for blood glucose control in type 2 diabetes.

1 November 2017 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
HYHea Min Yu
Hea Min Yu
HCHyo Kyun Chung
Hyo Kyun Chung
KKKoon Soon Kim
Koon Soon Kim
JLJae Min Lee
Jae Min Lee
JHJun Hwa Hong
Jun Hwa Hong
KPKang Seo Park
Kang Seo Park


31 August 2023 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
JOJaewon Oh
Jaewon Oh
WKWonho Kim
Wonho Kim
GKGee-Hee Kim
Gee-Hee Kim
HKHack-Lyoung Kim
Hack-Lyoung Kim
SPSang-Don Park
Sang-Don Park
RIRESOLVE-INT Investigators
RESOLVE-INT Investigators
Introduction Patients with hypertension and additional cardiovascular risk factors pose a challenge by requiring more intensive blood pressure (BP) control. Single-pill combination (SPC) therapy can benefit these patients by improving medication adherence. Methods This prospective, multicenter observational study assessed the real-world safety and effectiveness of an SPC containing olmesartan, amlodipine, and hydrochlorothiazide (O/A/H) in South Korean patients with hypertension and cardiovascular risk factors. BP control rates, defined as the percentage of patients achieving systolic BP (SBP) < 130 mmHg and diastolic BP (DBP) < 80 mmHg for intensive BP control, and < 140 mmHg and < 90 mmHg, respectively, for standard BP control, were investigated across various cardiovascular risk groups, along with changes in SBP and DBP from baseline to week 24. Results The most prevalent cardiovascular risk factor was age (≥ 45 years in men, ≥ 55 years in women, 86.1%), followed by cardiovascular diseases (64.4%), dyslipidemia (53.7%), body mass index ≥ 25 kg/m2 (53.5%), and diabetes mellitus (DM) (46.3%). Switching to O/A/H showed significant BP reduction, with a mean change of − 17.8 mmHg/− 9.3 mmHg in SBP/DBP within 4 weeks. The intensive BP control rate was 41.4% (95% confidence interval [CI] 39.5, 43.4), and the standard BP control rate was 73.3% (95% CI 71.5, 75.1), with better control rates in the risk age group (43.1% and 74.1%, respectively) and cardiovascular disease group (42.0% and 73.8%, respectively). The DM group had relatively lower control rates (37.5% for intensive control and 69.4% for standard control). Common adverse drug reactions included dizziness (2.91%), hypotension (1.51%), and headaches (0.70%). Conclusion The SPC therapy of O/A/H caused a rapid and sustained reduction in SBP/DBP in patients’ hypertension and additional cardiovascular risk factors. The therapy was safe and well tolerated. Study Registration Number KCT0003401 (https://cris.nih.go.kr/cris/search/detailSearch.do/20795).